Rescue therapy for steroid refractory acute severe ulcerative colitis: More choice, better outcomes?

Journal of Gastroenterology and Hepatology (Australia)

Volumn 27, Issue 3, 2012, Pages 417-418

  Gearry, Richard B ^a,b   Falvey, James D ^a,b  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b CHRISTCHURCH HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CORTISONE; CYCLOSPORIN; INFLIXIMAB; LOW MOLECULAR WEIGHT HEPARIN; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PLACEBO; SERUM ALBUMIN; STEROID;

ALBUMIN BLOOD LEVEL; CLINICAL DECISION MAKING; CLOSTRIDIUM DIFFICILE; COLON RESECTION; CYTOMEGALOVIRUS; DISEASE SEVERITY; DRUG DOSE REDUCTION; EDITORIAL; ENTERITIS; FLUID RESUSCITATION; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; HYPOTENSION; MORTALITY; PERITONITIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; TACHYCARDIA; THROMBOEMBOLISM; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT PLANNING; TREATMENT RESPONSE; ULCERATIVE COLITIS; VENOUS THROMBOEMBOLISM;

EID: 84857320080     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2012.07063.x     Document Type: Editorial

References (14)

1. Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br. Med. J. 1955; 2: 1041-8.
2. Travis SP, Farrant JM, Ricketts C etal. Predicting outcome in severe ulcerative colitis. Gut 1996; 38: 905-10.
3. Hearing SD, Norman M, Probert CS, Haslam N, Dayan CM. Predicting therapeutic outcome in severe ulcerative colitis by measuring in vitro steroid sensitivity of proliferating peripheral blood lymphocytes. Gut 1999; 45: 382-8.
4. Falvey J, Greenwood R, Creed T etal. Mortality in ulcerative colitis-what should we tell our patients? Three year mortality following admission for the treatment of ulcerative colitis: a 6year retrospective case review Frontline. Gastroenterology 2010; 1: 35-41.
5. Lichtiger S, Present DH, Kornbluth A etal. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N. Engl. J. Med. 1994; 330: 1841-5.
6. Van Assche G, D'Haens G, Noman M etal. Randomized, double-blind comparison of 4mg/kg versus 2mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology 2003; 125: 1025-31.
7. Sands BE, Tremaine WJ, Sandborn WJ etal. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm. Bowel Dis. 2001; 7: 83-8.
8. Jarnerot G, Hertervig E, Friis-Liby I etal. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005; 128: 1805-11.
9. Gustavsson A, Halfvarson J, Magnuson A, Sandberg-Gertzen H, Tysk C, Jarnerot G. Long-term colectomy rate after intensive intravenous corticosteroid therapy for ulcerative colitis prior to the immunosuppressive treatment era. Am. J. Gastroenterol. 2007; 102: 2513-19.
10. Dean KE, Hikaka J, Huakau JT etal. Infliximab or cyclosporine for acute severe ulcerative colitis: A retrospective analysis. J. Gastroenterol. Hepatol. 2012; 27: 487-92.
11. D'Haens G, Lemmens L, Geboes K etal. Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. Gastroenterology 2001; 120: 1323-9.
12. Laharie D, Bourreille A, Branche J etal. Cyclosporin versus infliximab in severe acute ulcerative colitis refractory to intravenous steroids: a randomized trial. Gastroenterology 2011; 140: S-112.
13. Williams JG. Comparison of infliximab and ciclosporin in steroid resistant ulcerative colitis: a trial. Cited 19 Nov 2011. Available from 2011.
14. Novacek G, Weltermann A, Sobala A etal. Inflammatory bowel disease is a risk factor for recurrent venous thromboembolism. Gastroenterology 2010; 139: 779-87. 87 e1.